Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles

Want, Muzamil Y.; Yadav, Priya; Khan, Rakin; Chouhan, Garima; Islamuddin, Mohammad; Aloyouni, Sheka Yagub; Chattopadhyay, Asoke P.; Alomar, Suliman Yousef; Afrin, Farhat

doi:10.2147/ijn.s268548

Cited by 13 publications

(10 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Similarly, gold NPs showed antileishmanial activity against L. donovani, as noted in the parasites' morphological changes and a considerable reduction in P.G. 71 Citrate-reduced GNPs functionalized with lipoic acid (LA) conjugated to Amp B showed ∼5-fold enhanced antileishmanial activity compared with Amp B alone. There was also enhanced expression of interferon-γ and IL-12 and a subsequent Th1 response.…”

Section: Metal and Metal Oxidesmentioning

confidence: 99%

“…It indicates the potential of phytochemical-stabilized gold NPs as a safe and effective alternative for antileishmanial activity . Similarly, gold NPs showed antileishmanial activity against L. donovani , as noted in the parasites’ morphological changes and a considerable reduction in P.G . Citrate-reduced GNPs functionalized with lipoic acid (LA) conjugated to Amp B showed ∼5-fold enhanced antileishmanial activity compared with Amp B alone.…”

Section: Nanodrug Delivery Systems Utilized During Leishmaniasis Trea...mentioning

confidence: 99%

See 1 more Smart Citation

Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review

Tambe,

Nag,

Pandya

et al. 2024

ACS Infect. Dis.

View full text Add to dashboard Cite

Leishmaniasis, one of the most overlooked tropical diseases, is a life-threatening illness caused by the parasite Leishmania donovani that is prevalent in underdeveloped nations. Over 350 million individuals in more than 90 different nations worldwide are at risk of contracting the disease, which has a current fatality rate of 50 000 mortalities each year. The administration of liposomal Amp B, pentavalent antimonials, and miltefosine are still considered integral components of the chemotherapy regimen. Antileishmanial medications fail to treat leishmaniasis because of their numerous drawbacks. These include inadequate effectiveness, toxicity, undesired side effects, drug resistance, treatment duration, and cost. Consequently, there is a need to overcome the limitations of conventional therapeutics. Nanotechnology has demonstrated promising outcomes in addressing these issues because of its small size and distinctive characteristics, such as enhanced bioavailability, lower toxicity, biodegradability, and targeted drug delivery. This review is an effort to highlight the recent progress in various nanodrug delivery systems (nDDSs) over the past five years for treating leishmaniasis. Although the preclinical outcomes of nDDSs have shown promising treatment for leishmaniasis, further research is needed for their clinical translation. Advancement in three primary priority domains�molecular diagnostics, clinical investigation, and knowledge dissemination and standardization�is imperative to propel the leishmaniasis field toward translational outcomes.

show abstract

Section: Metal and Metal Oxidesmentioning

confidence: 99%

Section: Nanodrug Delivery Systems Utilized During Leishmaniasis Trea...mentioning

confidence: 99%

Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review

Tambe,

Nag,

Pandya

et al. 2024

ACS Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…These nanoformulations can be synthesized through chemical, physical, or biological processes and are solely generated from metal precursors such as silver and gold [ 114 – 115 ]. In addition, MNPs have been widely used in therapy, drug delivery, targeting, and imaging [ 116 – 117 ]. Current studies have directed the use of metallic nanoparticles such as silver and gold nanoparticles against Leishmania sp.…”

Section: Reviewmentioning

confidence: 99%

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review

Dourado,

Silva Medeiros,

do Nascimento Alencar

et al. 2024

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

Leishmaniasis is a neglected tropical disease that has affected more than 350 million people worldwide and can manifest itself in three different forms: cutaneous, mucocutaneous, or visceral. Furthermore, the current treatment options have drawbacks which compromise efficacy and patient compliance. To face this global health concern, new alternatives for the treatment of leishmaniasis have been explored. Curcumin, a polyphenol obtained from the rhizome of turmeric, exhibits leishmanicidal activity against different species of Leishmania spp. Although its mechanism of action has not yet been fully elucidated, its leishmanicidal potential may be associated with its antioxidant and anti-inflammatory properties. However, it has limitations that compromise its clinical use. Conversely, nanotechnology has been used as a tool for solving biopharmaceutical challenges associated with drugs, such as curcumin. From a drug delivery standpoint, nanocarriers (1–1000 nm) can improve stability, increase solubility, promote intracellular delivery, and increase biological activity. Thus, this review offers a deep look into curcumin-loaded nanocarriers intended for the treatment of leishmaniasis.

show abstract

“…However, these tests are not very sensitive and are mainly used for low throughput screenings. Furthermore, direct counting could also be used to evaluate the leishmanicidal activity of tested compounds both in promastigote (motility of promastigotes and examination of non-viable parasites after staining) [71] and in amastigote (microscopic counting of infected macrophages and the number of parasites per macrophage after staining) assays [71]. This method has the advantage of not requiring expensive equipment, but it is time-consuming, laborious to perform, unsuitable for large-scale screening, and suffers from a lack of reproducibility.…”

Section: Challenges Involved In Implementing Exploratory Screening To Identify In Vitro Hit Compounds Against Leishmaniamentioning

confidence: 99%

Challenges and Tools for In Vitro Leishmania Exploratory Screening in the Drug Development Process: An Updated Review

Cohen

Azas

2021

Pathogens

View full text Add to dashboard Cite

Leishmaniases are a group of vector-borne diseases caused by infection with the protozoan parasites Leishmania spp. Some of them, such as Mediterranean visceral leishmaniasis, are zoonotic diseases transmitted from vertebrate to vertebrate by a hematophagous insect, the sand fly. As there is an endemic in more than 90 countries worldwide, this complex and major health problem has different clinical forms depending on the parasite species involved, with the visceral form being the most worrying since it is fatal when left untreated. Nevertheless, currently available antileishmanial therapies are significantly limited (low efficacy, toxicity, adverse side effects, drug-resistance, length of treatment, and cost), so there is an urgent need to discover new compounds with antileishmanial activity, which are ideally inexpensive and orally administrable with few side effects and a novel mechanism of action. Therefore, various powerful approaches were recently applied in many interesting antileishmanial drug development programs. The objective of this review is to focus on the very first step in developing a potential drug and to identify the exploratory methods currently used to screen in vitro hit compounds and the challenges involved, particularly in terms of harmonizing the results of work carried out by different research teams. This review also aims to identify innovative screening tools and methods for more extensive use in the drug development process.

show abstract

Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles

Cited by 13 publications

References 64 publications

Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review

Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review

Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review

Challenges and Tools for In Vitro Leishmania Exploratory Screening in the Drug Development Process: An Updated Review

Contact Info

Product

Resources

About